{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:43:12Z","timestamp":1792111392929,"version":"4.4.0"},"reference-count":65,"publisher":"Akademiai Kiado Zrt.","issue":"2","funder":[{"name":"Kocaeli University Scientific Research Projects Coordination Unit","award":["BAPSIS-2336, 2020"],"award-info":[{"award-number":["BAPSIS-2336, 2020"]}]}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["AMicr"],"published-print":{"date-parts":[[2024,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Carbapenem-resistant <jats:italic>Enterobacterales<\/jats:italic> (CRE) have become a major public health problem worldwide. The aim of this study was to investigate efficacy of ceftazidime\/avibactam and plazomicin on carbapenem-resistant <jats:italic>Klebsiella pneumoniae<\/jats:italic> and <jats:italic>Escherichia coli<\/jats:italic> isolates. Susceptibility of imipenem, meropenem, ertapenem, ceftazidime\/avibactam and plazomicin was investigated by broth-microdilution method. Major carbapenemases NDM, VIM, IMP, KPC, OXA-48 as well as other \u03b2-lactamases namely, TEM, SHV, OXA-1-like, CTX-M, ACC, FOX, MOX, DHA, CIT, EBC, VEB, GES, PER were investigated by PCR. A total of 120 carbapenem-resistant isolates (60\u2009<jats:italic>E. coli<\/jats:italic> and 60\u2009<jats:italic>K. pneumoniae<\/jats:italic>) were included in this study and <jats:italic>bla<\/jats:italic><jats:sub>OXA-48-like<\/jats:sub> was found in 78.33%, <jats:italic>bla<\/jats:italic><jats:sub>NDM<\/jats:sub> in 26.66%, <jats:italic>bla<\/jats:italic><jats:sub>KPC<\/jats:sub> in 7.5%, <jats:italic>bla<\/jats:italic><jats:sub>IMP<\/jats:sub> in 5.83%, and <jats:italic>bla<\/jats:italic><jats:sub>VIM<\/jats:sub> in 5%. Among 94 isolates with the <jats:italic>bla<\/jats:italic><jats:sub>OXA-48-like<\/jats:sub> gene, 22.3% were resistant to ceftazidime\/avibactam and 51.1% were resistant to plazomicin. Of 32 isolates with <jats:italic>bla<\/jats:italic><jats:sub>NDM<\/jats:sub>, 31 (96.9%) were resistant to ceftazidime\/avibactam and 30 (93.75%) were resistant to plazomicin, and both antibiotics had limited effects against <jats:italic>bla<\/jats:italic><jats:sub>NDM<\/jats:sub> carriers (<jats:italic>P<\/jats:italic> &lt; 0.001). Of the 12 isolates with <jats:italic>bla<\/jats:italic><jats:sub>NDM+OXA-48<\/jats:sub> combination, 11 (91.7%) were resistant to ceftazidime\/avibactam and plazomicin. The effect of both antibiotics was significantly lower in strains with <jats:italic>bla<\/jats:italic><jats:sub>NDM+OXA-48<\/jats:sub> combination (<jats:italic>P<\/jats:italic> &lt; 0.005).<\/jats:p><jats:p>The most common carbapenemase genes in this study were <jats:italic>bla<\/jats:italic><jats:sub>OXA-48-like<\/jats:sub> and <jats:italic>bla<\/jats:italic><jats:sub>NDM<\/jats:sub>. Ceftazidime\/avibactam demonstrated a good efficacy among OXA-48 producing <jats:italic>K. pneumoniae<\/jats:italic> and <jats:italic>E. coli<\/jats:italic>, however, plazomicin had a significantly lower antibacterial effect in our study. Both antimicrobial agents should be considered as an option by evaluating combined susceptibility results and gene patterns obtained by regional and global molecular data in the treatment of CRE infections.<\/jats:p>","DOI":"10.1556\/030.2024.02292","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T13:32:58Z","timestamp":1717594378000},"page":"110-120","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy of ceftazidime\/avibactam and plazomicin on carbapenem-resistant Klebsiella pneumoniae and Escherichia coli"],"prefix":"10.1556","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4134-1587","authenticated-orcid":true,"given":"Sevil","family":"\u00d6zta\u015f","sequence":"first","affiliation":[{"name":"Vocational School of Health Services, Karabuk University, Karab\u00fck, 78600, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do\u011fanhan Kadir","family":"Er","sequence":"additional","affiliation":[{"name":"Molecular Gastroenterology and Hepatology Department, Gastroenterology and Hepatology Institute, Kocaeli University, Kocaeli, 41000, T\u00fcrkiye"},{"name":"Medical Microbiology Department Faculty of Medicine, Kocaeli University, Kocaeli, 41000, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devrim","family":"D\u00fcndar","sequence":"additional","affiliation":[{"name":"Medical Microbiology Department Faculty of Medicine, Kocaeli University, Kocaeli, 41000, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sema A\u015fk\u0131n","family":"Ke\u00e7eli","sequence":"additional","affiliation":[{"name":"Medical Microbiology Department Faculty of Medicine, Kocaeli University, Kocaeli, 41000, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"B1","article-title":"World Health Organization antimicrobial resistance","unstructured":"World Health Organization antimicrobial resistance. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/antimicrobial-resistance [Accessed 5 July 2023]."},{"key":"B2","series-title":"Eur Centre Dis Prev Control","article-title":"Assessing the health burden of infections with antibiotic-resistant bacteria in the EU\/EEA, 2016-2020","author":"European Centre for Disease Prevention and Control (ECDC) Technical Report","unstructured":"European Centre for Disease Prevention and Control (ECDC) Technical Report. Assessing the health burden of infections with antibiotic-resistant bacteria in the EU\/EEA, 2016-2020. Eur Centre Dis Prev Control. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/health-burden-infections-antibiotic-resistant-bacteria-2016-2020 [Accessed 4 July 2023]."},{"issue":"10","key":"B3","series-title":"Eur J Clin Microbiol Infect Dis","first-page":"2053","article-title":"Treatment for carbapenem resistant Enterobacterales infections: recent advances and future directions","volume":"40","author":"Tompkins K","year":"2021","unstructured":"Tompkins K, Duin DV. Treatment for carbapenem resistant Enterobacterales infections: recent advances and future directions. Eur J Clin Microbiol Infect Dis 2021; 40(10): 2053\u20132068. https:\/\/doi.org\/10.1007\/s10096-021-04296-1."},{"key":"B4","article-title":"World Health Organization WHO publishes list of bacteria for which new antibiotics are urgently needed","year":"2017","unstructured":"World Health Organization WHO publishes list of bacteria for which new antibiotics are urgently needed. 2017. https:\/\/www.who.int\/news\/item\/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed [Accessed 3 July 2023]."},{"key":"B5","series-title":"Int J Mol Sci","first-page":"5090","article-title":"Molecular mechanisms, epidemiology, and clinical importance of \u03b2-lactam resistance in Enterobacteriaceae","volume":"21","author":"Angelis DG","year":"2020","unstructured":"Angelis DG, Giacomo DP, Posteraro B, Sanguinetti M, Tumbarello M. Molecular mechanisms, epidemiology, and clinical importance of \u03b2-lactam resistance in Enterobacteriaceae. Int J Mol Sci 2020; 21: 5090. https:\/\/doi.org\/10.3390\/ijms21145090."},{"key":"B6","series-title":"Antimicrob Agents Chemother","first-page":"e01076","article-title":"Past and present perspectives on \u03b2-lactamases","volume":"62","author":"Bush K","year":"2018","unstructured":"Bush K. Past and present perspectives on \u03b2-lactamases. Antimicrob Agents Chemother 2018; 62: e01076\u201318. https:\/\/doi.org\/10.1128\/AAC.01076-18."},{"key":"B7","series-title":"Philos Trans R Soc B Biol Sci","first-page":"321","article-title":"The structure of \u03b2-lactamases","volume":"289","author":"Ambler RP","year":"1980","unstructured":"Ambler RP. The structure of \u03b2-lactamases. Philos Trans R Soc B Biol Sci 1980; 289: 321\u2013331. https:\/\/doi.org\/10.1098\/rstb.1980.0049."},{"key":"B8","series-title":"Front Mol Biosci","first-page":"16","article-title":"Structural and mechanistic basis for extended-spectrum drug-resistance mutations in altering the specificity of TEM, CTX-M, and KPC \u03b2-lactamases","volume":"5","author":"Palzkill T","year":"2018","unstructured":"Palzkill T. Structural and mechanistic basis for extended-spectrum drug-resistance mutations in altering the specificity of TEM, CTX-M, and KPC \u03b2-lactamases. Front Mol Biosci 2018; 5: 16. https:\/\/doi.org\/10.3389\/fmolb.2018.00016."},{"key":"B9","series-title":"J Mol Biol","first-page":"3472","article-title":"Lactamases and \u03b2-lactamase inhibitors in the\u00a021st century","volume":"431","author":"Tooke CL","year":"2019","unstructured":"Tooke CL, Hinchliffe P, Bragginton EC, Colenso CK, Hirvonen VHA, Takebayashi Y, et\u00a0al. Lactamases and \u03b2-lactamase inhibitors in the\u00a021st century. J Mol Biol 2019; 431: 3472\u20133500. https:\/\/doi.org\/10.1016\/j.jmb.2019.04.002."},{"issue":"1","key":"B10","series-title":"Med Sci","first-page":"1","article-title":"Carbapenem resistance: a review","volume":"6","author":"Codjoe FS","year":"2018","unstructured":"Codjoe FS, Donkor ES. Carbapenem resistance: a review. Med Sci 2018; 6(1): 1. https:\/\/doi.org\/10.3390\/medsci6010001."},{"issue":"7","key":"B11","series-title":"Clin Infect Dis","first-page":"521","article-title":"Epidemiology and diagnostics of carbapenem resistance in gram-negative bacteria","volume":"69","author":"Nordmann P","year":"2019","unstructured":"Nordmann P, Poirel L. Epidemiology and diagnostics of carbapenem resistance in gram-negative bacteria. Clin Infect Dis 2019; 69(7): 521\u2013528. https:\/\/doi.org\/10.1093\/cid\/ciz824."},{"issue":"1","key":"B12","series-title":"Ther Adv Infect Dis","first-page":"15","article-title":"Carbapenem resistance: overview of the problem and future perspectives","volume":"3","author":"Meletis G","year":"2016","unstructured":"Meletis G. Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis 2016; 3(1): 15\u201321. https:\/\/doi.org\/10.1177\/2049936115621709."},{"key":"B13","series-title":"J Glob Antimicrob Resist","first-page":"18","article-title":"Resistance to ceftazidime-avibactam and underlying mechanisms","volume":"22","author":"Wang Y","year":"2020","unstructured":"Wang Y, Wang J, Wang R, Cai Y. Resistance to ceftazidime-avibactam and underlying mechanisms. J Glob Antimicrob Resist 2020; 22: 18\u201327. https:\/\/doi.org\/10.1016\/j.jgar.2019.12.009."},{"key":"B14","series-title":"Core Evid","first-page":"13","article-title":"Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of gram-negative bacterial infections","volume":"9","author":"Wiens PL","year":"2014","unstructured":"Wiens PL, Walkty A, Karlowsky JA. Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of gram-negative bacterial infections. Core Evid 2014; 9: 13\u201325. https:\/\/doi.org\/10.2147\/CE.S40698."},{"issue":"6","key":"B15","series-title":"Drugs","first-page":"675","article-title":"Ceftazidime-avibactam: a review in the treatment of serious gram-negative bacterial infections","volume":"78","author":"Shirley M","year":"2018","unstructured":"Shirley M. Ceftazidime-avibactam: a review in the treatment of serious gram-negative bacterial infections. Drugs 2018; 78(6): 675\u2013692. https:\/\/doi.org\/10.1007\/s40265-018-0902-x."},{"issue":"4","key":"B16","series-title":"Clin Infect Dis","first-page":"704","article-title":"Plazomicin: a new aminoglycoside","volume":"70","author":"Saravolatz LD","year":"2020","unstructured":"Saravolatz LD, Stein GE. Plazomicin: a new aminoglycoside. Clin Infect Dis 2020; 70(4): 704\u2013709. https:\/\/doi.org\/10.1093\/cid\/ciz640."},{"issue":"4","key":"B17","series-title":"Expert Rev Anti Infect Ther","first-page":"495","article-title":"Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin","volume":"10","author":"Zhanel GG","year":"2012","unstructured":"Zhanel GG, Lawson CD, Zelenitsky S, Findlay B, Schweizer F, Adam H, et\u00a0al. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev Anti Infect Ther 2012; 10(4): 495\u2013473. https:\/\/doi.org\/10.1586\/eri.12.25."},{"issue":"1","key":"B18","series-title":"Antimicrob Agents Chemother","first-page":"e02068","article-title":"In vitro activity of plazomicin against gram-negative and gram-positive bacterial pathogens isolated from patients in canadian hospitals from 2013 to 2017 as part of the CANWARD surveillance study","volume":"63","author":"Walktya A","year":"2019","unstructured":"Walktya A, Karlowskya JA, Baxtera MR, Adama JH, Zhanel GG. In vitro activity of plazomicin against gram-negative and gram-positive bacterial pathogens isolated from patients in canadian hospitals from 2013 to 2017 as part of the CANWARD surveillance study. Antimicrob Agents Chemother 2019; 63(1): e02068\u201318. https:\/\/doi.org\/10.1128\/AAC.02068-18."},{"issue":"1","key":"B19","series-title":"Infect Dis Ther","first-page":"75","article-title":"Continuous evolution: perspective on the epidemiology of carbapenemase resistance among enterobacterales and other gram-negative bacteria","volume":"10","author":"Hansen GT","year":"2021","unstructured":"Hansen GT. Continuous evolution: perspective on the epidemiology of carbapenemase resistance among enterobacterales and other gram-negative bacteria. Infect Dis Ther 2021; 10(1): 75\u201392. https:\/\/doi.org\/10.1007\/s40121-020-00395-2."},{"key":"B20","article-title":"EUCAST reading guide for broth dilution","author":"European Committee on Antimicrobial Susceptibility Testing (EUCAST)","year":"2022","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). EUCAST reading guide for broth dilution, Version 4.0; 2022. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Disk_test_documents\/2022_manuals\/Reading_guide_BMD_v_4.0_2022.pdf [Accessed 1 May 2022]."},{"key":"B21","article-title":"European committee on antimicrobial susceptibility testing breakpoint tables for interpretation of MICs and zone diameters","author":"European Society of Clinical Microbiology and Infectious Diseases","year":"2022","unstructured":"European Society of Clinical Microbiology and Infectious Diseases. European committee on antimicrobial susceptibility testing breakpoint tables for interpretation of MICs and zone diameters, Version 12.0; 2022. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_12.0_Breakpoint_Tables.pdf [Accessed 30 May 2022]."},{"key":"B22","series-title":"Performance Standards for antimicrobial susceptibility testing","author":"Clinical And Laboratory Standards Institute","year":"2023","unstructured":"Clinical And Laboratory Standards Institute. Performance Standards for antimicrobial susceptibility testing, 33rd Edition; 2023. http:\/\/em100.edaptivedocs.net\/GetDoc.aspx?doc=CLSI%20M100%20ED33:2023&scope=user [Accessed 10 April 2023]."},{"key":"B23","article-title":"Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST","author":"European Committee on Antimicrobial Susceptibility Testing (EUCAST)","year":"2022","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST, Version 12.0; 2022. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/QC\/v_12.0_EUCAST_QC_tables_routine_and_extended_QC.pdf [Accessed 2 May 2022]."},{"issue":"5","key":"B24","series-title":"J Clin Microbiol","first-page":"1915","article-title":"Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis","volume":"42","author":"Moskowitz SM","year":"2004","unstructured":"Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 2004; 42(5): 1915\u20131922. https:\/\/doi.org\/10.1128\/JCM.42.5.1915-1922.2004."},{"issue":"3","key":"B25","series-title":"J Antimicrob Chemother","first-page":"490","article-title":"Development of a set of multiplex PCR assays for the detection of genes encoding important \u03b2-lactamases in Enterobacteriaceae","volume":"65","author":"Dallenne C","year":"2010","unstructured":"Dallenne C, Costa AD, Decre D, Favier C, Arlet G. Development of a set of multiplex PCR assays for the detection of genes encoding important \u03b2-lactamases in Enterobacteriaceae. J Antimicrob Chemother 2010; 65(3): 490\u2013495. https:\/\/doi.org\/10.1093\/jac\/dkp498."},{"issue":"12","key":"B26","series-title":"J Clin Microbiol","first-page":"3877","article-title":"Laboratory detection of Enterobacteriaceae that produce carbapenemases","volume":"50","author":"Doyle D","year":"2012","unstructured":"Doyle D, Peirano G, Lascols C, Lloyd T, Church DL, Pitout JDD. Laboratory detection of Enterobacteriaceae that produce carbapenemases. J Clin Microbiol 2012; 50(12): 3877\u20133880. https:\/\/doi.org\/10.1128\/JCM.02117-12."},{"issue":"8","key":"B27","series-title":"Clin Microbiol Infect","first-page":"943","article-title":"Management of carbapenem-resistant Enterobacteriaceae infections","volume":"25","author":"Mangoni DE","year":"2019","unstructured":"Mangoni DE, Andini R, Zampino R. Management of carbapenem-resistant Enterobacteriaceae infections. Clin Microbiol Infect 2019; 25(8): 943\u2013950. https:\/\/doi.org\/10.1016\/j.cmi.2019.04.013."},{"key":"B28","series-title":"Infect Drug Resist","first-page":"4363","article-title":"Emerging carbapenem-resistant Enterobacteriaceae infection, its epidemiology and novel treatment options: a review","volume":"14","author":"Tilahun M","year":"2021","unstructured":"Tilahun M, Kassa Y, Gedefie A, Ashagire M. Emerging carbapenem-resistant Enterobacteriaceae infection, its epidemiology and novel treatment options: a review. Infect Drug Resist 2021; 14: 4363\u20134374. https:\/\/doi.org\/10.2147\/IDR.S337611."},{"key":"B29","series-title":"StatPearls (Internet)","article-title":"Gram negative bacteria","author":"Oliveira J","unstructured":"Oliveira J, Reygaert WC. Gram negative bacteria. In: StatPearls (Internet). StatPearls Publishing. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538213\/ [Accessed 3 July 2023]."},{"key":"B30","series-title":"Front Cell Infect Microbiol","article-title":"In vitro activity comparison of ceftazidime-avibactam and aztreonam-avibactam against bloodstream infections with carbapenem-resistant organisms in China","volume":"11","author":"Wei Y","year":"2021","unstructured":"Wei Y, Xio L, Luo Q, Chen Y, Ji J, Ying C, et\u00a0al. In vitro activity comparison of ceftazidime-avibactam and aztreonam-avibactam against bloodstream infections with carbapenem-resistant organisms in China. Front Cell Infect Microbiol 2021; 11: 780365. https:\/\/doi.org\/10.3389\/fcimb.2021.780365."},{"key":"B31","series-title":"Drug Des Devel Ther","first-page":"3095","article-title":"The potential use of ceftazidime-avibactam against carbapenem resistant Klebsiella pneumoniae clinical isolates harboring different carbapenemase types in a Thai University Hospital","volume":"15","author":"Nasomsong W","year":"2021","unstructured":"Nasomsong W, Nulsopapon P, Changpradub D, Pongchaidecha M, Pungcharoenkijkul S, Juntanawiwat P, et\u00a0al. The potential use of ceftazidime-avibactam against carbapenem resistant Klebsiella pneumoniae clinical isolates harboring different carbapenemase types in a Thai University Hospital. Drug Des Devel Ther 2021; 15: 3095\u20133104. https:\/\/doi.org\/10.2147\/DDDT.S321147."},{"issue":"2","key":"B32","series-title":"J Infect Chemother","first-page":"192","article-title":"Molecular characterization of carbapenemase producing Klebsiella pneumoniae strains by multiplex PCR and PFGE methods: the first K. pneumoniae isolates co-producing OXA-48\/KPC and KPC\/NDM in Turkey","volume":"28","author":"Gen\u00e7 S","year":"2022","unstructured":"Gen\u00e7 S, Kolayl\u0131 F, \u00d6z\u00e7elik E. Molecular characterization of carbapenemase producing Klebsiella pneumoniae strains by multiplex PCR and PFGE methods: the first K. pneumoniae isolates co-producing OXA-48\/KPC and KPC\/NDM in Turkey. J Infect Chemother 2022; 28(2): 192\u2013198. https:\/\/doi.org\/10.1016\/j.jiac.2021.10.009."},{"issue":"1","key":"B33","series-title":"Mikrobiyol Bul","first-page":"21","article-title":"Investigation of carbapenemases in carbapenem-resistant Escherichia coli and Klebsiella pneumoniae strains isolated in 2014 in Turkey","volume":"50","author":"\u00c7akar A","year":"2016","unstructured":"\u00c7akar A, Aky\u00f6n Y, G\u00fcr D, Karatuna O, \u00d6\u011f\u00fcn\u00e7 D, Baysan B\u00d6, et\u00a0al. Investigation of carbapenemases in carbapenem-resistant Escherichia coli and Klebsiella pneumoniae strains isolated in 2014 in Turkey. Mikrobiyol Bul 2016; 50(1): 21\u201333. https:\/\/doi.org\/10.5578\/mb.10695."},{"issue":"4","key":"B34","series-title":"Acta Microbiol Immunol Hung","first-page":"256","article-title":"Ceftazidime-avibactam susceptibility among carbapenem-resistant Enterobacteales in a pilot study in Turkey","volume":"68","author":"Ozger HS","year":"2021","unstructured":"Ozger HS, Evren E, Y\u0131ld\u0131z SS, Erol C, Bayraktar F, Azap O, et\u00a0al. Ceftazidime-avibactam susceptibility among carbapenem-resistant Enterobacteales in a pilot study in Turkey. Acta Microbiol Immunol Hung 2021; 68(4): 256\u2013261. https:\/\/doi.org\/10.1556\/030.2021.01525."},{"issue":"2","key":"B35","series-title":"Lancet Infect Dis","first-page":"153","article-title":"Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study","volume":"7","author":"Grundmann H","year":"2017","unstructured":"Grundmann H, Glasner C, Albiger B, Aanensen DM, Tomlinson CT, Andrasevi\u0107 AT, et\u00a0al. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis 2017; 7(2): 153\u2013163. https:\/\/doi.org\/10.1016\/S1473-3099(16)30257-2."},{"issue":"4","key":"B36","series-title":"Virulance","first-page":"460","article-title":"The global epidemiology of carbapenemase-producing Enterobacteriaceae","volume":"8","author":"Duin VD","year":"2017","unstructured":"Duin VD, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulance 2017; 8(4): 460\u2013469. https:\/\/doi.org\/10.1080\/21505594.2016.1222343."},{"issue":"7","key":"B37","series-title":"Eur J Clin Microbiol Infect Dis","first-page":"1251","article-title":"The emergence of carbapenemase blaNDM genotype among carbapenem-resistant Enterobacteriaceae isolates from Egyptian cancer patients","volume":"39","author":"Tawfick MM","year":"2020","unstructured":"Tawfick MM, Alshareef WA, Bendary HA, Elmahalawy H, Abdulall K. The emergence of carbapenemase blaNDM genotype among carbapenem-resistant Enterobacteriaceae isolates from Egyptian cancer patients. Eur J Clin Microbiol Infect Dis 2020; 39(7): 1251\u20131259. https:\/\/doi.org\/10.1007\/s10096-020-03839-2."},{"issue":"1","key":"B38","series-title":"BMC Infect Dis","first-page":"542","article-title":"Molecular epidemiology and outcome of carbapenem-resistant Enterobacterales in Saudi Arabia","volume":"22","author":"Alraddadi BM","year":"2022","unstructured":"Alraddadi BM, Heaphy ELG, Aljishi Y, Ahmed W, Eljaaly K, Al-Turkistani, et\u00a0al. Molecular epidemiology and outcome of carbapenem-resistant Enterobacterales in Saudi Arabia. BMC Infect Dis 2022; 22(1): 542. https:\/\/doi.org\/10.1186\/s12879-022-07507-y."},{"issue":"3","key":"B39","series-title":"Antibiotics","first-page":"355","article-title":"Antimicrobial activity profiles and potential antimicrobial regimens against carbapenem-resistant Enterobacterales isolate from multi-centers in Western Thailand","volume":"11","author":"Nulsopapon P","year":"2022","unstructured":"Nulsopapon P, Pongchaidecha M, Nasomsong W, Polwichahi P, Suphankong S, Sirichote P, et\u00a0al. Antimicrobial activity profiles and potential antimicrobial regimens against carbapenem-resistant Enterobacterales isolate from multi-centers in Western Thailand. Antibiotics 2022; 11(3): 355. https:\/\/doi.org\/10.3390\/antibiotics11030355."},{"issue":"1","key":"B40","series-title":"Ann N Y Acad Sci","first-page":"61","article-title":"Plasmid evolution in carbapenemase-producing Enterobacteriaceae: a review","volume":"1457","author":"Kopotsa K","year":"2019","unstructured":"Kopotsa K, Sekyere JO, Mbelle NM. Plasmid evolution in carbapenemase-producing Enterobacteriaceae: a review. Ann N Y Acad Sci 2019; 1457(1): 61\u201391. https:\/\/doi.org\/10.1111\/nyas.14223."},{"key":"B41","series-title":"Acta Microbiol Immunol Hung","article-title":"Ceftazidime - avibactam susceptibility among carbapenem-resistant Enterobacterales in a pilot study in Turkey","volume":"29","author":"Ozger HS","year":"2021; Jul","unstructured":"Ozger HS, Evren E, Yildiz SS, Erol C, Bayrakdar F, Azap O, et\u00a0al. Ceftazidime - avibactam susceptibility among carbapenem-resistant Enterobacterales in a pilot study in Turkey. Acta Microbiol Immunol Hung 2021; Jul; 29. https:\/\/doi.org\/10.1556\/030.2021.01525."},{"issue":"2","key":"B42","series-title":"Lancet Infect Dis","first-page":"153","article-title":"Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study","volume":"7","author":"Grundmann H","year":"2017","unstructured":"Grundmann H, Glasner C, Albiger B, Aanensen DM, Tomlinson CT, Andrasevi\u0107 AT, et\u00a0al. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis 2017; 7(2): 153\u2013163. https:\/\/doi.org\/10.1016\/S1473-3099(16)30257-2."},{"issue":"6","key":"B43","series-title":"Clin Infect Dis","first-page":"754","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner FM","year":"2016","unstructured":"Wagenlehner FM, Sobel JD, Newell P, Armstrong J, Huang X, Stone GG, et\u00a0al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis 2016; 63(6): 754\u2013762. https:\/\/doi.org\/10.1093\/cid\/ciw378."},{"key":"B44","series-title":"Antimicrob Resist Infect Control","first-page":"2","article-title":"In vitro and in vivo bactericidal activity of ceftazidime-avibactam against carbapenemase\u2013producing Klebsiella pneumoniae","volume":"7","author":"Zhang W","year":"2018","unstructured":"Zhang W, Guo Y, Li J, Zhang Y, Yang Y, Dong D, et\u00a0al. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against carbapenemase\u2013producing Klebsiella pneumoniae. Antimicrob Resist Infect Control 2018; 7: 2\u20139. https:\/\/doi.org\/10.1186\/s13756-018-0435-9."},{"key":"B45","series-title":"Drug Des Devel Ther","first-page":"3095","article-title":"The potential use of ceftazidime-avibactam against carbapenem resistant Klebsiella pneumoniae clinical isolates harboring different carbapenemase types in a Thai University Hospital","volume":"15","author":"Nasomsong W","year":"2021","unstructured":"Nasomsong W, Nulsopapon P, Changpradub D, Pongchaidecha M, Pungcharoenkijkul S, Juntanawiwat P, et\u00a0al. The potential use of ceftazidime-avibactam against carbapenem resistant Klebsiella pneumoniae clinical isolates harboring different carbapenemase types in a Thai University Hospital. Drug Des Devel Ther 2021; 15: 3095\u20133104. https:\/\/doi.org\/10.2147\/DDDT.S321147."},{"issue":"8","key":"B46","series-title":"Antimicrob Agents Chemother","first-page":"e00313","article-title":"In vitro activity of plazomicin against gram-negative and gram-positive isolates collected from u.s. hospitals and comparative activities of aminoglycosides against carbapenem-resistant Enterobacteriaceae and isolates carrying carbapenemase genes","volume":"62","author":"Castanheira M","year":"2018","unstructured":"Castanheira M, Davis AP, Mendes RE, Serio AW, Krause KM, Flamm RK. In vitro activity of plazomicin against gram-negative and gram-positive isolates collected from u.s. hospitals and comparative activities of aminoglycosides against carbapenem-resistant Enterobacteriaceae and isolates carrying carbapenemase genes. Antimicrob Agents Chemother 2018; 62(8): e00313\u201318. https:\/\/doi.org\/10.1128\/aac.00313-18."},{"issue":"3","key":"B47","series-title":"Clin Infect Dis","first-page":"519","article-title":"Ceftazidime\/avibactam, meropenem\/vaborbactam, or both? clinical and formulary considerations","volume":"68","author":"Pogue JM","year":"2019","unstructured":"Pogue JM, Bonomo BA, Kaye KS. Ceftazidime\/avibactam, meropenem\/vaborbactam, or both? clinical and formulary considerations. Clin Infect Dis 2019; 68(3): 519\u2013524. https:\/\/doi.org\/10.1093\/cid\/ciy576."},{"key":"B48","series-title":"Front Cell Infect Microbiol","article-title":"Global threat of carbapenem-resistant gram-negative bacteria","volume":"12","author":"Jean SS","year":"2022","unstructured":"Jean SS, Harnod D, Hsueh PR. Global threat of carbapenem-resistant gram-negative bacteria. Front Cell Infect Microbiol 2022; 12: 823684. https:\/\/doi.org\/10.3389\/fcimb.2022.823684."},{"issue":"9","key":"B49","series-title":"Antimicrob Agents Chemother","first-page":"e00642","article-title":"Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae","volume":"61","author":"Haidar G","year":"2017","unstructured":"Haidar G, Clancy CJ, Chen L, Samanta P, Shields RK, Kreiswirth BN, et\u00a0al. Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother 2017; 61(9): e00642\u201317. https:\/\/doi.org\/10.1128\/AAC.00642-17."},{"issue":"5","key":"B50","series-title":"J\u00a0Antimicrob Chemother","first-page":"12241","article-title":"Ceftazidime\/avibactam resistance associated with L169P mutation in the omega loop of KPC-2","volume":"74","author":"Hemarajata P","year":"2019","unstructured":"Hemarajata P, Humphries RM. Ceftazidime\/avibactam resistance associated with L169P mutation in the omega loop of KPC-2. J\u00a0Antimicrob Chemother 2019; 74(5): 12241\u20131243. https:\/\/doi.org\/10.1093\/jac\/dkz026."},{"issue":"6","key":"B51","series-title":"Antimicrob Agents Chemother","first-page":"3509","article-title":"Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. Hospitals (2011 to 2013) and characterization of \u03b2-lactamase-producing strains","volume":"59","author":"Castanheira M","year":"2015","unstructured":"Castanheira M, Mills JC, Costello SE, Jones RN, Sader HS. Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. Hospitals (2011 to 2013) and characterization of \u03b2-lactamase-producing strains. Antimicrob Agents Chemother 2015; 59(6): 3509\u201317. https:\/\/doi.org\/10.1128\/aac.00163-15."},{"key":"B52","series-title":"Front Microbiol","article-title":"A selective medium for screening ceftazidime\/avibactam resistance in carbapenem-resistant Enterobacterales","volume":"13","author":"Zeng W","year":"2022","unstructured":"Zeng W, Liao W, Zhao Y, Wang L, Shu H, Jia H, et\u00a0al. A selective medium for screening ceftazidime\/avibactam resistance in carbapenem-resistant Enterobacterales. Front Microbiol 2022; 13: 956044. https:\/\/doi.org\/10.3389\/fmicb.2022.956044."},{"issue":"5","key":"B53","series-title":"Antimicrob Agents Chemother","first-page":"3163","article-title":"In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM global surveillance study (2012 to 2014)","volume":"60","author":"Jonge BLM","year":"2016","unstructured":"Jonge BLM, Karlowsky JA, Kazmierczak KM, Biedenbach DJ, Sahm DF, Nicholsa WW. In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM global surveillance study (2012 to 2014). Antimicrob Agents Chemother 2016; 60(5): 3163\u20139. https:\/\/doi.org\/10.1128\/AAC.03042-15."},{"issue":"12","key":"B54","series-title":"J Antimicrob Chemother","first-page":"3336","article-title":"Selection of mutants with resistance or diminished susceptibility to ceftazidime\/avibactam from ESBL- and AmpC-producing Enterobacteriaceae","volume":"73","author":"Livermore DM","year":"2018","unstructured":"Livermore DM, Mushtaq S, Doumith M, Jamrozy D, Nichols WW, Woodford N. Selection of mutants with resistance or diminished susceptibility to ceftazidime\/avibactam from ESBL- and AmpC-producing Enterobacteriaceae. J Antimicrob Chemother 2018; 73(12): 3336\u20133345. https:\/\/doi.org\/10.1093\/jac\/dky363."},{"issue":"7","key":"B55","series-title":"Antimicrob Agents Chemother","first-page":"3700","article-title":"Avibactam and inhibitor-resistant SHV beta-lactamases","volume":"59","author":"Winkler ML","year":"2015","unstructured":"Winkler ML, Papp-Wallace KM, Taracila MA, Bonomo RA. Avibactam and inhibitor-resistant SHV beta-lactamases. Antimicrob Agents Chemother 2015; 59(7): 3700\u20133709. https:\/\/doi.org\/10.1128\/AAC.04405-14."},{"issue":"2","key":"B56","series-title":"mSphere","article-title":"OXA-48-mediated ceftazidime-avibactam resistance is associated with evolutionary trade-offs","volume":"4","author":"Fr\u00f6hlich C","year":"2019","unstructured":"Fr\u00f6hlich C, Sorum V, Thomassen AM, Johnsen PJ, Leiros HS, Samuelsen O. OXA-48-mediated ceftazidime-avibactam resistance is associated with evolutionary trade-offs. mSphere 2019; 4(2): e00024-19. https:\/\/doi.org\/10.1128\/mSphere.00024-19."},{"issue":"7","key":"B57","series-title":"Clin Infect Dis","first-page":"565","article-title":"Treatment options for carbapenem-resistant gram-negative bacterial infections","volume":"69","author":"Doi Y","year":"2019","unstructured":"Doi Y. Treatment options for carbapenem-resistant gram-negative bacterial infections. Clin Infect Dis 2019; 69(7): 565\u2013575. https:\/\/doi.org\/10.1093\/cid\/ciz830."},{"issue":"10","key":"B58","series-title":"J Antimicrob Chemother","first-page":"2792","article-title":"In vitro activity of plazomicin against \u03b2-lactamase-producing carbapenem-resistant Enterobacteriaceae","volume":"72","author":"Zhang Y","year":"2017","unstructured":"Zhang Y, Kashikar A, Bush K. In vitro activity of plazomicin against \u03b2-lactamase-producing carbapenem-resistant Enterobacteriaceae. J Antimicrob Chemother 2017; 72(10): 2792\u20132795. https:\/\/doi.org\/10.1093\/jac\/dkx261."},{"issue":"2","key":"B59","series-title":"Antimicrob Agents Chemother","first-page":"e01711","article-title":"In vitro activity of plazomicin compared to amikacin, gentamicin, and tobramycin against multidrug-resistant aerobic gram-negative bacilli","volume":"64","author":"Fleischmann WA","year":"2020","unstructured":"Fleischmann WA, Quaintance KEG, Patel R. In vitro activity of plazomicin compared to amikacin, gentamicin, and tobramycin against multidrug-resistant aerobic gram-negative bacilli. Antimicrob Agents Chemother 2020; 64(2): e01711\u201319. https:\/\/doi.org\/10.1128\/aac.01711-19."},{"issue":"8","key":"B60","series-title":"J Antimicrob Chemother","first-page":"2061","article-title":"Activity of plazomicin against carbapenem-intermediate or resistant Escherichia coli isolates from the United States and international sites in relation to clonal background, resistance genes, co-resistance, and region","volume":"76","author":"Johnston BD","year":"2021","unstructured":"Johnston BD, Thuras P, Porter SB, Anacker M, Vonbank B, Vagnone SP, et\u00a0al. Activity of plazomicin against carbapenem-intermediate or resistant Escherichia coli isolates from the United States and international sites in relation to clonal background, resistance genes, co-resistance, and region. J Antimicrob Chemother 2021; 76(8): 2061\u20132070. https:\/\/doi.org\/10.1093\/jac\/dkab150."},{"issue":"3","key":"B61","series-title":"JAC Antimicrob Resist","first-page":"1","article-title":"Extended-spectrum \u03b2-lactamases: an update on their characteristics, epidemiology and detection","volume":"3","author":"Castanheira M","year":"2021","unstructured":"Castanheira M, Simner PJ, Bradford PA. Extended-spectrum \u03b2-lactamases: an update on their characteristics, epidemiology and detection. JAC Antimicrob Resist 2021; 3(3): 1\u201321. https:\/\/doi.org\/10.1093\/jacamr\/dlab092."},{"issue":"2","key":"B62","series-title":"Diagn Microbiol Infect Dis","article-title":"Distribution of genes encoding 16s rRNA methyltransferase in plazomicin-nonsusceptible carbapenemase-producing Enterobacterales in Brazil","volume":"99","author":"Bail L","year":"2021","unstructured":"Bail L, Ito CAS, Arend LNVS, Pilonetto M, Nogueira KS, Tuon FF. Distribution of genes encoding 16s rRNA methyltransferase in plazomicin-nonsusceptible carbapenemase-producing Enterobacterales in Brazil. Diagn Microbiol Infect Dis 2021; 99(2): 115239. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2020.115239."},{"issue":"3\u20134","key":"B63","series-title":"Indian J Med Microbiol","first-page":"313","article-title":"Expected plazomicin susceptibility in India based on the prevailing aminoglycoside resistance mechanisms in gram-negative organisms derived from whole-genome sequencing","volume":"38","author":"Pragasam KA","year":"2020","unstructured":"Pragasam KA, Jennifer SL, Solaimalai D, Sethuvel MPD, Rachel T, Elangovan D, et\u00a0al. Expected plazomicin susceptibility in India based on the prevailing aminoglycoside resistance mechanisms in gram-negative organisms derived from whole-genome sequencing. Indian J Med Microbiol 2020; 38(3\u20134): 313\u2013318. https:\/\/doi.org\/10.4103\/ijmm.IJMM_20_384."},{"issue":"3","key":"B64","series-title":"Drugs","first-page":"243","article-title":"Plazomicin: a novel aminoglycoside for the treatment of resistant gram-negative bacterial infections","volume":"79","author":"Eljaaly K","year":"2019","unstructured":"Eljaaly K, Alharbi A, Alshehri S, Ortwine JK, Pogue JM. Plazomicin: a novel aminoglycoside for the treatment of resistant gram-negative bacterial infections. Drugs 2019; 79(3): 243\u2013269. https:\/\/doi.org\/10.1007\/s40265-019-1054-3."},{"issue":"2","key":"B65","series-title":"Int J Antimicrob Agents","first-page":"278","article-title":"High prevalence of 16s rRNA methyltransferases among carbapenemase-producing Enterobacteriaceae in the UK and Ireland","volume":"52","author":"Taylor E","year":"2018","unstructured":"Taylor E, Sriskandan S, Woodford N, Hopkins KL. High prevalence of 16s rRNA methyltransferases among carbapenemase-producing Enterobacteriaceae in the UK and Ireland. Int J Antimicrob Agents 2018; 52(2): 278\u2013282. https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.03.016."}],"container-title":["Acta Microbiologica et Immunologica Hungarica"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/030\/71\/2\/article-p110.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/030\/71\/2\/article-p110.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/030\/71\/2\/article-p110.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T15:23:04Z","timestamp":1719933784000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/030\/71\/2\/article-p110.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":65,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.1556\/030.2024.02292","relation":{},"ISSN":["1217-8950","1588-2640"],"issn-type":[{"value":"1217-8950","type":"print"},{"value":"1588-2640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,2]]}}}